Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance

Journal of Clinical Investigation

Volumn 100, Issue 3, 1997, Pages 530-537

  Cavaghan, Melissa K ^a   Ehrmann, David A ^a   Byrne, Maria M ^a   Polonsky, Kenneth S ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Glucose intolerance; Insulin resistance; Insulin secretion; Non insulin dependent diabetes mellitus; Thiazeles

Indexed keywords

GLUCOSE; ORAL ANTIDIABETIC AGENT; PLACEBO; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030762562     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119562     Document Type: Article

References (62)

1. Diabetes mellitus: report of a WHO study group. 1985. WHO Tech. Rep. Ser. 727:9-17.
2. Edelstein, S.L., W.C. Knowler, R.P. Bain, R. Andres, E.L. Barrett-Connor, G.K. Dowse, S.M. Haffner, D.J. Pettitt, J.D. Sorkin, D.C. Muller, et al. 1997. Predictors of progression from impaired glucose tolerance to NIDDM. Diabetes. 46:701-710.
3. Lillioja, S., D.M. Mott, B.V. Howard, P.H. Bennett, H. Yki-Järvinen, D. Freymond, B.L. Nyomba, F. Zurlo, B. Swinburn, and C. Bogardus. 1988. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and crosssectional studies in Pima Indians. N. Engl. J. Med. 318:1217-1225.
4. Warram, J.H., B.C. Martin, A.S. Krolewski, J.S. Soeldner, and C.R. Kahn. 1990. Slow glucose removal rate and hyperinsulinemia predict the development of type II diabetes in the offspring of diabetic parents. Ann. Intern. Med. 113:909-915.
5. Haffner, S.M., M.P. Stern, H.P. Hazuda, M.D. Mitchell, and J.P. Patterson. 1988. Increased insulin concentrations in nondiabetic offspring of diabetic parents. N. Engl. J. Med. 319:1297-1301.
6. Eriksson, J., A. Franssila-Kallunki, A. Ekstrand, C. Saloranta, E. Widen, C. Schalin, and L. Groop. 1989. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 321:337-343.
7. O'Rahilly, S., R.C. Turner, and D.R. Matthew. 1988. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 318:1231-1239.
8. O'Meara, N.M., J. Sturis, E. Van Cauter, and K.S. Polonsky. 1993. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 92:262-271.
9. Byrne, M.M., J. Sturis, R.J. Sobel, and K.S. Polonsky. 1996. Elevated plasma glucose 2 h postchallenge predicts defects in β-cell function. Am. J. Physiol. 270:E572-E579.
10. Long, S.D., K. O'Brien, K.G. MacDonald, N. Leggett-Frazier, Jr., M.S. Swanson, W.J. Pories, and J.F. Caro. 1994. Weight loss in severely obese subjects prevents progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 17:372-375.
11. Melander, A., P.-O. Bitzén, G. Sartor, B. Schersten, and E. Wahlin-Boll. 1990. Will sulfonylurea treatment of impaired glucose tolerance delay development and complications of NIDDM? Diabetes Care. 13(Suppl. 3):53-58.
12. Knowler, W.C., G. Sartor, and B. Schersten. 1987. Effects of glucose tolerance and treatment of abnormal tolerance on mortality in Malmohus County, Sweden. Diabetologia. 28:541A. (Abstr.)
13. Rudnichi, A., A. Fontbonne, M. Safar, J.M. Bard, P. Vague, I. Juhan-Vague, E. Eschwege, and the BIGPRO Study Group. 1994. The effect of metformin on the metabolic anomalies associated with android type body fat distribution. Results of the BIGPRO Trial. Diabetes. (Suppl. 1):150A. (Abstr.)
14. Scheen, A.J., M.R. Letiexhe, and P.J. Lefèbvre. 1995. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabetic Med. 12:985-989.
15. Suter, S.L., J.J. Nolan, P. Wallace, B. Gumbiner, and J.M. Olefsky. 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
16. Nolan, J.J., B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-1193.
17. Berkowitz, K., R. Peters, S.L. Kjos, J. Goico, A. Marroquin, M.E. Dunn, A. Xiang, S. Azen, and T.A. Buchanan. 1996. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes. 45:1572-1579.
18. Fujiwara, T., S. Yoshioka, T. Yoshioka, I. Ushiyama, and H. Horikoshi. 1988. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1549-1558.
19. Inoue, I., K. Takahashi, S. Katayama, Y. Harada, K. Negishi, A. Itabshi, and J. Ishii. 1995. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metab. Clin. Exp. 44:1626-1630.
20. Iwamoto, Y., K. Kosaka, T. Kuzuya, Y. Akanuma, Y. Shigeta, and T. Kaneko. 1996. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 19:151-157.
21. DeSouza, C.J., J.H. Yu, D.D. Robinson, R.G. Ulrich, and M.D. Meglasson. 1995. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes. 44:984-991.
22. Sturis, J., W.L. Pugh, J. Tang, and K.S. Polonsky. 1995. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am. J. Physiol. 269:E786-E792.
23. Sreenan, S., J. Sturis, W. Pugh, C.F. Burant, and K.S. Polonsky. 1996. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am. J. Physiol. 271:E742-E747.
24. Bergman, R.N. 1989. Lilly Lecture 1989. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes. 38:1512-1527.
25. Byrne, M.M., J. Sturis, K. Clément, N. Vionnet, M.E. Pueyo, M. Stoffel, J.Takeda, P. Passa, D. Cohen, G.I. Bell, et al. 1994. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J. Clin. Invest. 93:1120-1130.
26. Byrne, M.M., J. Sturis, and K.S. Polonksy. 1995. Insulin secretion and clearance during low-dose graded glucose infusion. Am. J. Physiol. 268:E21-E27.
27. Sturis, J., E. Van Cauter, J.D. Blackman, and K.S. Polonsky. 1991. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J. Clin. Invest. 87:439-445.
28. Morgan, D.R., and A. Lazarow. 1963. Immunoassay of insulin: two antibody system: plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes. 12:115-125.
29. Faber, O.K., C. Binder, J. Markussen, L.G. Heding, V.K. Naithani, H. Kuzuya, P. Blix, D.L. Horwitz, and A.H. Rubenstein. 1978. Characterization of seven C-peptide antisera. Diabetes. 27(Suppl. 1):170-177.
30. Van Cauter, E., F. Mestrez, J. Sturis, and K.S. Polonksy. 1992. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 41:368-377.
31. Eaton, R.P., R.D. Allen, D.S. Schade, K.M. Erickson, and J. Standefer. 1980. Prehepatic insulin production in man: peripheral analysis using connecting peptide behavior. J. Clin. Endocrinol. Metab. 51:520-528.
32. Polonsky, K.S., J. Licinio-Paixao, B.D. Given, W. Pugh, P. Rue, J. Galloway, T. Karrison, and B. Frank. 1986. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J. Clin. Invest. 77:98-105.
33. Bergman, R.N., L.S. Phillips, and C. Cobelli. 1981. Physiologic evaluation of factors controlling glucose tolerance in man. J. Clin. Invest. 68:1456-1467.
34. Kahn, S.E., R.L. Prigeon, D.K. McCulloch, E.J. Boyko, R.N. Bergman, M.W. Schwartz, J.L. Neifing, W.K. Ward, J.C. Beard, J.P. Palmer, et al. 1993. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 42:1663-1672.
35. Jenkins, G.M., and D.G. Watts. 1968. Spectral Analysis and Its Applications. Holden Day, San Francisco. 525 pp.
36. Weir, G. 1982. Non-insulin-dependent diabetes mellitus: interplay between β-cell inadequacy and insulin resistance. Am. J. Med. 73:461-464.
37. Porte, D., Jr. 1991. Banting Lecture 1990. β-Cells in type II diabetes mellitus. Diabetes. 40:166-180.
38. DeFronzo, R.A., R.C. Bonadonna, and E. Ferrannini. 1992. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15:318-368.
39. Polonsky, K.S. 1995. Lilly Lecture 1994. The β-cell in diabetes: from molecular genetics to clinical research. Diabetes. 44:705-717.
40. Iwamoto, Y., T. Kuzuya, A. Matsuda, T. Awata, S. Kumakura, G. Inooka, and I. Shiraishi. 1991. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
41. Ehrmann, D.A., J. Stuns, M.M. Byrne, T. Karrison, R.L. Rosenfield, and K.S. Polonsky. 1995. Insulin secretory defects in polycystic ovary syndrome. J. Clin. Invest. 96:520-527.
42. Dunaif, A., and D.T. Finegood. 1996. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:942-947.
43. Dunaif, A., D. Scott, D. Finegood, B. Quintana, and R. Whitcomb. 1996. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:3299-3306.
44. Kosaka, K., T. Kuzuya, Y. Akanuma, and R. Hagura. 1980. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatement. Diabetologia. 18:23-28.
45. Vague, P., and J.P. Moulin. 1982. The defective glucose sensitivity of the β-cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metab. Clin. Exp. 31:139-142.
46. Hidaka, H., M. Nagulesparan, I. Klimes, R. Clark, H. Sasaki, S.L. Aronoff, B. Vasquez, A.M. Rubenstein, and R.H. Unger. 1985. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J. Clin. Endocrinol. Metab. 54:217-222.
47. Rosetti, L., A. Giaccari, and R.A. DeFronzo. 1990. Glucose toxicity. Diabetes Care. 13:610-629.
48. Leahy, J.L., S. Bonner-Weir, and G.C. Weir. 1992. β-Cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care. 15:442-453.
49. Yki-Järvinen, H. 1992. Glucose toxicity. Endocrine Rev. 13:415-431.
50. Helmrich, S.P., D.R. Ragland, R.W. Leung, and R.S. Paffenbarger, Jr. 1991. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 325:147-152.
51. Eriksson, K.F., and F. Lindgarde. 1991. Prevention of type II (non-insulin-dependent) diabetes mellitus by diet and physical exercise:the 6-year Malmo feasibility study. Diabetologia. 34:891-898.
52. McGarry, J.D. 1994. Disordered metabolism in diabetes: have we underemphasized the fat component? J. Cell. Biochem. 55S:29-38.
53. Unger, R.H. 1995. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes. 44:863-870.
54. Stein, D.T., V. Esser, B.E. Stevenson, K.E. Lane, J.H. Whiteside, M.B. Daniels, S. Chen, and J.D. McGarry. 1996. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J. Clin. Invest. 97: 2728-2735.
55. Sako, Y., and V.E. Grill. 1990. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology. 127: 1580-1589.
56. Elks, M.L. 1993. Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology. 133:208-214.
57. Zhou, Y.-P., and V.E. Grill. 1994. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J. Clin. Invest. 93:870-876.
58. Keller, H., and W. Wahli. 1993. Peroxisome proliferator-activated receptors: A link between endocrinology and nutrition? Trends Endocrinol. Metab. 4:291-296.
59. Ibrahimi, A., L. Teboul, D. Gaillard, E.Z. Amri, G. Ailhaud, P. Young, M.A. Cawthorne, and P.A. Grimaldi. 1994. Evidence for a common mechanism of action for free fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46:1070-1076.
60. Brandes, R., R. Arad, and J. Bar-Tana. 1995. Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells. Biochem. Pharmacol. 50:1949-1951.
61. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:813-819.
62. Lehmann, J.M., L.B. Moore, T.A. Smith-Oliver, W.O. Wilkinson, T.M. Willson, and S.A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:12953-12956.